Moreover, simultaneous RASSF1A methylation and KRAS mutation shortened survival in patients with NSCLC [141], suggesting that RASSF1A methylation may synergically promote the growth of lung cancer with KRAS mutation by inhibiting the Hippo pathway, which needs further confirmation. This evidence concerns the gene KRAS and lung cancer.